OVID SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 13, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 12, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 18, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 12, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 13, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 13, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Ovid Therapeutics Reports Second Quarter 2026 Financial Results and Pipeline Progress

Aug 13, 2026

8-K

Ovid Therapeutics Announces Executive Leadership Transition

Jul 8, 2026

8-K

Ovid Therapeutics Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 11, 2026

8-K

Ovid Therapeutics Appoints Dr. Anna Greka to Board of Directors

Jun 3, 2026

8-K

Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results

May 12, 2026

8-K

Ovid Therapeutics Announces Expiration and Exercise of Series A Warrants

Apr 20, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B3

SHARE RESALE REGISTRATION | Shares: 29,856,031

Apr 27, 2026

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 125,064,325 | Warrants amount: 67,400,000

Dec 22, 2025

424B5

ATM | Offering amount: $75,000,000

Nov 15, 2023

424B5

ATM | Offering amount: $75,000,000

Nov 20, 2020

424B5

SHELF OFFERING | Shares amount: 6,250,000 | Share price: $8.00 | Offering amount: $50,000,000.00 | Bank: Cowen, William Blair, RBC Capital Markets, Ladenburg Thalmann

Aug 26, 2020

424B5

ATM | Offering amount: $50,000,000

Nov 12, 2019

Registrations

TYPE

HEADLINE

FILED AT

S-3

SHARE RESALE REGISTRATION

Apr 21, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 18, 2026

S-3

SHARE RESALE REGISTRATION

Dec 15, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 14, 2024

S-3

SHELF | ATM | Offering amount: $250,000,000.00 EFFECTIVE

Nov 3, 2023

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 5, 2023

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 27, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 27, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Nov 7, 2025

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Oct 27, 2025

PREM14A

Form PREM14A - Preliminary proxy statements relating to merger or acquisition

Oct 27, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 22, 2025

Ownerships

TYPE

HEADLINE

FILED AT

144

Form 144 - Report of proposed sale of securities

Aug 24, 2026

144

Form 144 - Report of proposed sale of securities

Aug 14, 2026

SCHEDULE 13G/A

ADAR1 Capital Management, LLC (Filed by)

Aug 14, 2026

SCHEDULE 13G/A

RA CAPITAL MANAGEMENT, L.P. (Filed by)

Aug 14, 2026

SCHEDULE 13G/A

EVENTIDE ASSET MANAGEMENT, LLC (Filed by)

Aug 14, 2026

SCHEDULE 13G/A

BALYASNY ASSET MANAGEMENT L.P. (Filed by)

Aug 14, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 27, 2026

CORRESP

Form CORRESP - Correspondence

Apr 23, 2026

LETTER

Form UPLOAD - SEC-generated letter

Apr 23, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Dec 23, 2025

CORRESP

Form CORRESP - Correspondence

Dec 19, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Nov 16, 2023

Ovid Therapeutics Inc. OVID · SEC Filings